← Human Trials & Peer-Reviewed Studies
Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy
Plain-language guide to PMID 17381500 (2007): open-label randomized controlled trial study of Insulin Glargine and Insulin Detemir in 320 subjects.
Key Facts
- PMID
- 17381500
- Journal
- Diabetic medicine : a journal of the British Diabetic Association
- Year
- 2007
- Study type
- Randomized Controlled Trial
- Authors
- Pieber TR et al. (7 authors)
- DOI
- 10.1111/j.1464-5491.2007.02113.x
- Registered trial
- NCT00312104
What This Study Did, in Plain Language
What Was Tested
Researchers studied Insulin Glargine and Insulin Detemir in this randomized controlled trial publication.
To compare glycaemic control and risk of hypoglycaemia of twice-daily insulin detemir with once-daily insulin glargine in subjects with Type 1 diabetes.
Who Took Part
According to the abstract, 320 subjects were involved.
By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, both men and women.
In this 26-week, multicentre, open-label, parallel-group trial, 320 subjects with Type 1 diabetes received either insulin detemir twice daily or insulin glargine once daily. each in combination with premeal insulin aspart.
How the Study Was Run
In design terms this was a randomized, open-label, multicenter and parallel-group study.
The subjects were allocated by chance, so the Insulin Glargine group and the comparison group should start out alike.
Being open-label, the Insulin Glargine study did not mask who received what.
Running at several centres spread the Insulin Glargine study over different clinics and patient groups.
The Insulin Glargine group and the comparison group ran side by side rather than switching.
What Was Measured
The subject headings attached to it are Austria, Blood Glucose, Diabetes Mellitus, Type 1, Germany, Glycated Hemoglobin, Hypoglycemia and Hypoglycemic Agents.
What This Means in Plain Language
The paper is a randomized, open-label and multicenter study of Insulin Glargine and Insulin Detemir in 320 subjects.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 10 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2007 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.
More context: the Insulin Glargine compound page and the Insulin Detemir compound page.
Our Notes on the Compounds
Insulin Glargine: A long-acting insulin analog given once daily; brands include Lantus, Toujeo, Basaglar and Semglee.
Insulin Detemir: A long-acting basal insulin analog sold as Levemir.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.